StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$161.52+0.73 (+0.45%)

Close on Nov 2, 2026Market cap $308.21BP/E 22.6Yield –

Novartis YoY Growth in the U.S. by Year

YoY Growth in the U.S. (% USD / cc) (%)

Novartis YoY Growth in the U.S.: 25.0% in FY2025, up 71.0 pts from a year earlier.

Latest, FY2025
25.0%
Period ended Dec 31, 2025
Change on a year earlier
+71.0 pts
-46.0% in FY2024
History
8 years
Since FY2018
Sources
8
Documents cited below

Where the FY2025 figure comes from

“|| Diovan Group | Established brands | Hypertension | 35 | 25 | 569 | 1 | 1 | 604 | 2 | 2”

Source: Novartis Form 6-K (0001114448-26-000007) ↗

Reported in Form 6-K & Form 20-F.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedYoY Growth in the U.S. (% USD / cc) (%)Year on yearSource
FY2025Dec 31, 202525.0%+71.0 ptsNovartis Form 6-K (0001114448-26-000007) ↗
FY2024Dec 31, 2024-46.0%-41.0 ptsNovartis Form 6-K (0001370368-25-000007) ↗
FY2023Dec 31, 2023-5.0%-13.0 ptsNovartis Form 6-K (0001370368-24-000007) ↗
FY2022Dec 31, 20228.0%+67.0 ptsNovartis Form 6-K (0001370368-23-000008) ↗
FY2021Dec 31, 2021-59.0%-103.0 ptsNovartis Form 6-K (0001370368-22-000009) ↗
FY2020Dec 31, 202044.0%+42.0 ptsNovartis Form 6-K (0001370368-21-000008) ↗
FY2019Dec 31, 20192.0%+5.0 ptsNovartis Form 6-K (0001370368-20-000007) ↗
FY2018Dec 31, 2018-3.0%–Novartis Form 6-K (0001370368-19-000006) ↗

Cite this data

StockData. (2026). Novartis YoY Growth in the U.S. (%), annual FY2018–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-diovan-group-us-yoy-pct

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.